Tonix Pharmaceuticals Holding Corp

The Reverse Stock Split Proposal asks shareholders to authorize the Board to implement one or more reverse stock splits of common stock within a two-year period at ratios between 1:2 and 1:250, with the Board retaining discretion on timing and exact ratios. Management seeks this authority primarily to provide flexibility to address potential non-compliance with Nasdaq minimum bid price requirements and to preserve the Company’s listing on Nasdaq, which they view as beneficial for liquidity and shareholder value. The proposal is framed as preventative and discretionary—the Board would only effect a reverse split if it determined it necessary or beneficial, and even then could choose not to proceed. Key context includes prior reverse split activity (a 1:100 reverse split effected on February 5, 2025) and recent Nasdaq rule changes that limit the ability of companies to repeatedly use reverse splits to regain compliance; those rules mean that if the Company uses another reverse split and later fails minimum bid requirements within certain windows, Nasdaq may proceed directly to delisting without offering a compliance period. The proposal therefore includes a broad range of ratios to preserve Board flexibility but the wide range increases the risk of materially reducing the share count and creating large odd-lot holdings; it also raises potential anti-takeover implications because additional authorized but unissued shares would remain available. The Board recommends a vote “FOR” arguing the possible benefits to liquidity and continued listing; shareholders should weigh these potential benefits against risks including uncertain impact on market capitalization, possible adverse rule interactions with Nasdaq’s amended listing rules, and dilution risk from increased available authorized shares post-split.

The 2026 Stock Incentive Plan Proposal requests shareholder approval of a new equity plan reserving 1,000,000 shares (with an evergreen annual increase formula) to grant options, RSUs, SARs, restricted stock, and cash awards to employees, directors and consultants. Management seeks approval to ensure the company can attract, retain and incentivize talent while conserving cash—particularly important for a commercial biopharma with limited cash resources. The Plan includes governance features aimed at aligning interests and preventing misuse: a prohibition on liberal share recycling, a repricing prohibition without shareholder approval, a one-year minimum vesting (with limited 5% exception), limits on dividends/dividend equivalents, annual director award limits, and a clawback clause. It also contains an evergreen provision that automatically increases the reserve annually, which could lead to material future dilution; the Board retains discretion to limit or forego these increases. The Plan is designed to comply with Nasdaq and tax rules (including ISO limitations and Section 409A considerations) and includes typical change-in-control and adjustment protections. The Board recommends a vote 'FOR', arguing the plan is necessary to remain competitive and align employees with shareholder interests, while shareholders should consider dilution potential (estimated ~4.9% fully-diluted if all 1,000,000 shares issued), the evergreen feature, and the breadth of delegated administrative discretion to the Compensation Committee.